Medication Monitor

Generic Name (Trade Name—Company)
February 1, 2011


(Nexiclon XR—NextWave)
Extended-release tablets, suspension approved


Treatment of hypertension

Clonidine extended-release tablets and suspension have been approved by FDA. Both formulations are indicated to be taken once daily, either alone or in combination with other antihypertensive agents. The tablets will be marketed in two strengths—0.17 mg and 0.26 mg—and the suspension will be available in a 0.09 mg/mL formulation.